CCND1, an oncogene at the 11q13.3 locus and it’s products have been reported to drive cell proliferation, angiogenesis, and drug resistance; CCND1, FGF expression (mainly FGF3/4/19), and FADD overexpression or co-expansion, which was negatively correlated with CD4+ T cell number and dendritic cell infiltration, suggesting that its expansion may reduce immune activity in breast cancer cells. Here, CCND1 is linked to breast carcinoma.